Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 7.71
(-2.28%)
SEK 7.71
(-2.28%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 71.11 Million SEK | 95.32% |
| 2023 | 36.41 Million SEK | 64.42% |
| 2022 | 22.14 Million SEK | 81.83% |
| 2021 | 12.17 Million SEK | -29.5% |
| 2020 | 17.27 Million SEK | 51.24% |
| 2019 | 11.42 Million SEK | -4.56% |
| 2018 | 11.96 Million SEK | -0.1% |
| 2017 | 11.98 Million SEK | 40.7% |
| 2016 | 8.51 Million SEK | 19.58% |
| 2015 | 7.12 Million SEK | 3.8% |
| 2014 | 6.86 Million SEK | -8.83% |
| 2013 | 7.52 Million SEK | -38.13% |
| 2012 | 12.16 Million SEK | -79.26% |
| 2011 | 58.62 Million SEK | -76.96% |
| 2010 | 254.41 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 52.75 Million SEK | 16.56% |
| 2024 Q4 | 71.11 Million SEK | 34.82% |
| 2024 Q1 | 53.14 Million SEK | 45.96% |
| 2024 Q2 | 45.25 Million SEK | -14.84% |
| 2023 Q1 | 20.37 Million SEK | -7.97% |
| 2023 Q4 | 36.41 Million SEK | 77.68% |
| 2023 Q3 | 20.49 Million SEK | 6.46% |
| 2023 FY | 36.41 Million SEK | 64.42% |
| 2023 Q2 | 19.24 Million SEK | -5.55% |
| 2022 Q2 | 37.22 Million SEK | -3.35% |
| 2022 Q4 | 22.14 Million SEK | -5.42% |
| 2022 Q1 | 38.52 Million SEK | 216.28% |
| 2022 FY | 22.14 Million SEK | 81.83% |
| 2022 Q3 | 23.41 Million SEK | -37.11% |
| 2021 Q3 | 21.95 Million SEK | 100.59% |
| 2021 Q2 | 10.94 Million SEK | -19.36% |
| 2021 Q4 | 12.17 Million SEK | -44.53% |
| 2021 Q1 | 13.57 Million SEK | -21.43% |
| 2021 FY | 12.17 Million SEK | -29.5% |
| 2020 Q1 | 10.28 Million SEK | -9.94% |
| 2020 FY | 17.27 Million SEK | 51.24% |
| 2020 Q2 | 9.36 Million SEK | -8.92% |
| 2020 Q3 | 9.31 Million SEK | -0.53% |
| 2020 Q4 | 17.27 Million SEK | 85.38% |
| 2019 Q2 | 12.58 Million SEK | -0.1% |
| 2019 FY | 11.42 Million SEK | -4.56% |
| 2019 Q4 | 11.42 Million SEK | -18.73% |
| 2019 Q3 | 14.05 Million SEK | 11.72% |
| 2019 Q1 | 12.59 Million SEK | 5.23% |
| 2018 Q2 | 7.21 Million SEK | -34.14% |
| 2018 Q4 | 11.96 Million SEK | 12.67% |
| 2018 Q3 | 10.62 Million SEK | 47.34% |
| 2018 Q1 | 10.94 Million SEK | -8.63% |
| 2018 FY | 11.96 Million SEK | -0.1% |
| 2017 Q3 | 11.89 Million SEK | 41.5% |
| 2017 Q2 | 8.4 Million SEK | -2.62% |
| 2017 Q4 | 11.98 Million SEK | 0.77% |
| 2017 FY | 11.98 Million SEK | 40.7% |
| 2017 Q1 | 8.62 Million SEK | 1.34% |
| 2016 Q1 | 6.67 Million SEK | -6.32% |
| 2016 FY | 8.51 Million SEK | 19.58% |
| 2016 Q3 | 7.55 Million SEK | 1.31% |
| 2016 Q4 | 8.51 Million SEK | 12.72% |
| 2016 Q2 | 7.45 Million SEK | 11.77% |
| 2015 Q1 | 6.5 Million SEK | -5.23% |
| 2015 FY | 7.12 Million SEK | 3.8% |
| 2015 Q3 | 8.97 Million SEK | 32.62% |
| 2015 Q4 | 7.12 Million SEK | -20.67% |
| 2015 Q2 | 6.76 Million SEK | 4.11% |
| 2014 Q2 | 8.04 Million SEK | -3.17% |
| 2014 Q1 | 8.3 Million SEK | 10.43% |
| 2014 Q4 | 6.86 Million SEK | -2.49% |
| 2014 FY | 6.86 Million SEK | -8.83% |
| 2014 Q3 | 7.03 Million SEK | -12.57% |
| 2013 Q3 | 7.22 Million SEK | 0.0% |
| 2013 Q4 | 7.52 Million SEK | 4.1% |
| 2013 FY | 7.52 Million SEK | -38.13% |
| 2013 Q1 | - SEK | -100.0% |
| 2012 Q1 | 28.83 Million SEK | -50.82% |
| 2012 FY | 12.16 Million SEK | -79.26% |
| 2012 Q3 | 12.29 Million SEK | -54.55% |
| 2012 Q2 | 27.05 Million SEK | -6.17% |
| 2012 Q4 | 12.16 Million SEK | -1.12% |
| 2011 Q2 | 25.32 Million SEK | 0.0% |
| 2011 FY | 58.62 Million SEK | -76.96% |
| 2011 Q3 | 39.32 Million SEK | 55.28% |
| 2011 Q4 | 58.62 Million SEK | 49.07% |
| 2010 FY | 254.41 Million SEK | 0.0% |
| 2010 Q4 | 254.41 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -662.169% |
| Amniotics AB (publ) | 10.54 Million SEK | -574.296% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1506.823% |
| BioArctic AB (publ) | 139.5 Million SEK | 49.02% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 95.458% |
| Saniona AB (publ) | 86.08 Million SEK | 17.384% |
| Simris Alg AB (publ) | 148.93 Million SEK | 52.25% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -74.057% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1752.996% |
| NextCell Pharma AB | 13.68 Million SEK | -419.525% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -416.412% |
| AcouSort AB (publ) | 10.37 Million SEK | -585.277% |
| Active Biotech AB (publ) | 13.4 Million SEK | -430.731% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 33.282% |
| Camurus AB (publ) | 414.81 Million SEK | 82.856% |
| Cantargia AB (publ) | 54.97 Million SEK | -29.376% |
| Genovis AB (publ.) | 98.04 Million SEK | 27.465% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -284.546% |
| Mendus AB (publ) | 51.22 Million SEK | -38.835% |
| Kancera AB (publ) | 17.97 Million SEK | -295.583% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -514.729% |
| LIDDS AB (publ) | 3.75 Million SEK | -1793.45% |
| Lipum AB (publ) | 7.53 Million SEK | -843.46% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1278.79% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 42.637% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -2914.752% |
| OncoZenge AB (publ) | 1.69 Million SEK | -4085.874% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 85.251% |
| Xintela AB (publ) | 14.01 Million SEK | -407.442% |
| Ziccum AB (publ) | 6.38 Million SEK | -1013.306% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -271.102% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 1.019% |
| CombiGene AB (publ) | 4.15 Million SEK | -1611.213% |
| Intervacc AB (publ) | 21.68 Million SEK | -228.035% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -105.526% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -166.28% |
| Corline Biomedical AB | 6.78 Million SEK | -947.548% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -15.909% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -341.261% |
| Aptahem AB (publ) | 8.99 Million SEK | -690.391% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -54.002% |
| Fluicell AB (publ) | 8.91 Million SEK | -697.734% |
| Biovica International AB (publ) | 34.76 Million SEK | -104.556% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -509.513% |
| Abliva AB (publ) | 16.78 Million SEK | -323.801% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 66.86% |
| 2cureX AB (publ) | 2.93 Million SEK | -2323.101% |
| I-Tech AB | 16.2 Million SEK | -338.865% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 94.003% |
| Cyxone AB (publ) | 4.69 Million SEK | -1415.083% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -433.598% |
| Biosergen AB | 5.08 Million SEK | -1298.584% |
| Nanologica AB (publ) | 79.32 Million SEK | 10.348% |
| SynAct Pharma AB | 51.83 Million SEK | -37.203% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -794.679% |
| BioInvent International AB (publ) | 90.45 Million SEK | 21.376% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1268.985% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 60.838% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -3864.214% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -458.051% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -879.587% |